Emergent BioSolutions Inc.: financial analysis
Ratios worked out from 10 fiscal years of Emergent BioSolutions Inc.'s statements, compared with 102 companies in Pharmaceutical.
Emergent BioSolutions Inc. scorecard#
Passes 11 of the 25 checks that could be worked out: strongest in shareholder returns (2 of 3), weakest in growth (1 of 6). Fiscal year 2025; market cap of Oct 29, 2026.
Valuation3 of 5
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✓Price to book below its peers' median0.7×Price to book 0.7× against Pharmaceutical's median of 3.2×.
- ✓Price to sales below its peers' median0.6×Price to sales 0.6× against Pharmaceutical's median of 3.5×.
- ✓Free cash flow yield above 5%43.0%Free cash flow is 43.0% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 4.92% (2026-11-20).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth1 of 6
- ✗Revenue grew in the newest year-28.8%Revenue down 28.8% in fiscal 2025.
- ✗Revenue up more than 5% a year over three years-12.7%-12.7% a year over the three years to fiscal 2025.
- ✗Faster growth over three years than its peers' median-12.7%-12.7% a year against Pharmaceutical's median of 2.5% (65 companies).
- ✓Earnings per share grew in the newest year0.93 vs -3.60Diluted EPS 0.93 in fiscal 2025 against -3.60 the year before (report's currency).
- ✗Net income higher than five years earlier$53 M$53 M in fiscal 2025 against $306 M in 2020.
- ✗Revenue rose in at least four of the last five years1 of 5Revenue rose in 1 of the five years to fiscal 2025.
Profitability3 of 6
- ✓Profitable in the newest year$53 MNet income $53 M in fiscal 2025.
- ✗Profitable in each of the last five years2 of 5Profitable in 2 of the five years to fiscal 2025.
- ✓Operating margin above its peers' median13.5%13.5% against Pharmaceutical's median of 1.8% (74 companies).
- ✗Return on equity above 15%10.5%10.5% in fiscal 2025.
- ✗Return on invested capital above 10%6.4%6.4% in fiscal 2025.
- ✓Operating margin wider than three years earlier13.5%13.5% in fiscal 2025 against -15.2% in 2022.
Financial health2 of 5
- ✓Short-term assets cover short-term liabilities5.0×Current ratio 5.01 at the end of fiscal 2025.
- ✗Debt below equity1.1×Debt to equity 1.13 at the end of fiscal 2025.
- ✓Net debt below three years of EBITDA2.0×Net debt 2.0 times EBITDA in fiscal 2025.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years2 of 3Positive in 2 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone1.40Z-score 1.40 (distress zone) for fiscal 2025.
Shareholder returns2 of 3
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year7.0%Diluted shares up 7.0% in fiscal 2025.
- ✓Dividends and buybacks above 3% of the market value6.8%Dividends and buybacks were 6.8% of the market value.
- ✓Free cash flow covers dividends and buybacks$157 MFree cash flow $157 M against $25 M paid out in fiscal 2025.
Worked out from the statements as filed (sec), the medians of Pharmaceutical, the 10-year Treasury yield of Nov 20, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
What the 2025 statements show#
Each line is an observation with its numbers, not a judgement of the company.
Worth a look
- Revenue fell 28.8% against the year before.
- The share count rose 7.0% in the year.
Piotroski F-score
Nine yes/no tests of whether the company's finances improved in the year. One point each.
- Made a profityes
- Operations brought in cashyes
- Return on assets roseyes
- Cash from operations exceeds profityes
- Long-term debt fell against assetsyes
- Current ratio roseyes
- No new shares issuedyes
- Gross margin roseyes
- Asset turnover roseno
Altman Z-score
A 1968 formula that weighs five balance-sheet ratios. It was built on listed manufacturers and says less about other kinds of company.
| Part | Ratio | Weight | Points |
|---|---|---|---|
| Working capital to assets | 0.40 | × 1.2 | 0.48 |
| Retained earnings to assets | -0.12 | × 1.4 | -0.17 |
| Operating income to assets | 0.08 | × 3.3 | 0.25 |
| Market value to liabilities | 0.46 | × 0.6 | 0.27 |
| Revenue to assets | 0.56 | × 1 | 0.56 |
Where the return on equity comes from
The DuPont split: margin, times how hard the assets work, times how much of them is financed by others.
Profitability#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Gross margin | 56.1% | 34.7% | 30.3% | 34.3% | 50.3% | 53.3% | 57% | |
| Operating margin | 13.5% | -10.4% | -69.2% | -15.2% | 19.3% | 1.8% | 70% | |
| Net margin | 7.1% | -18.3% | -72.5% | -18.9% | 12.4% | -1.5% | 67% | |
| Return on equity | 10.5% | -33.7% | -74.7% | -14.1% | 14.3% | -0.9% | 67% | |
| Return on assets | 3.9% | -11.9% | -30.5% | -6.9% | 7.5% | -1.3% | 66% | |
| Return on invested capital | 6.4% | — | — | — | 13.7% | 14.4% | 33% |
Growth#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Revenue growth | -28.8% | -0.5% | -6.1% | -37.0% | 12.5% | 7.3% | 5% | |
| Revenue growth, 3 years a year | -12.7% | -16.2% | -12.7% | 0.4% | 31.4% | 2.5% | 12% | |
| Revenue growth, 5 years a year | -14.0% | -1.2% | 6.1% | 14.8% | 29.4% | 6.0% | 7% | |
| Net income growth | — | — | — | — | -28.2% | 14.3% | — | |
| Earnings per share growth | — | — | — | — | -28.5% | 12.4% | — |
Financial strength#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Debt to equity | 1.13× | 1.45× | 1.34× | 1.02× | 0.53× | 0.66× | 29% | |
| Net debt | $384 M | $601 M | $757 M | $771 M | $274 M | $188 M | 45% | |
| Net debt to EBITDA | 1.96× | — | — | — | 0.59× | 3.19× | 62% | |
| Interest cover | — | — | -8.26× | -4.56× | 9.90× | 1.11× | — | |
| Current ratio | 5.01× | 3.69× | 1.04× | 0.98× | 3.40× | 1.98× | 88% | |
| Equity share of assets | 39.6% | 34.7% | 35.6% | 43.8% | 54.5% | 47.3% | 42% |
Cash#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Free cash flow | $157 M | $36 M | $-258 M | $-150 M | $96 M | $8 M | 67% | |
| Free cash flow margin | 21.1% | 3.4% | -24.6% | -13.4% | 5.4% | 6.0% | 91% | |
| Cash conversion | 324.3% | — | — | — | 145.9% | 136.7% | 79% | |
| Capital spending share of revenue | 1.9% | 2.2% | 4.9% | 10.4% | 12.6% | 2.6% | — |
Efficiency#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Asset turnover | 0.55× | 0.65× | 0.42× | 0.36× | 0.61× | 0.55× | 49% |
How each figure is worked out#
- Gross margin
- Gross profit as a share of revenue.
- Operating margin
- Operating income as a share of revenue.
- Net margin
- Net income as a share of revenue.
- Return on equity
- Net income as a share of shareholders' equity (the average of the start and the end of the year). Not given when equity is negative.
- Return on assets
- Net income as a share of total assets (average of the year).
- Return on invested capital
- Operating income after tax, as a share of debt plus equity less cash (average of the year). The tax rate is the year's own: income tax over pre-tax income.
- Revenue growth
- Revenue against the year before.
- Revenue growth, 3 years a year
- The yearly rate that takes revenue of three years earlier to this year's.
- Revenue growth, 5 years a year
- The yearly rate that takes revenue of five years earlier to this year's.
- Net income growth
- Net income against the year before. Only when both years were profitable.
- Earnings per share growth
- Diluted earnings per share against the year before. Only when both were positive.
- Debt to equity
- Total debt divided by shareholders' equity. Not given when equity is negative.
- Net debt
- Total debt less cash. Negative means more cash than debt.
- Net debt to EBITDA
- Debt less cash, divided by operating income plus depreciation and amortization: roughly the years of operating earnings needed to repay it.
- Interest cover
- Operating income divided by the interest paid on debt.
- Current ratio
- Assets due within a year divided by liabilities due within a year.
- Equity share of assets
- Shareholders' equity as a share of total assets.
- Free cash flow
- Cash from operations less capital spending.
- Free cash flow margin
- Free cash flow as a share of revenue.
- Cash conversion
- Cash from operations as a share of net income. Only when the year was profitable.
- Capital spending share of revenue
- Capital spending as a share of revenue.
- Buyback yield
- Shares bought back in the fiscal year as a share of today's market value.
- Shareholder yield
- Dividends plus buybacks as a share of today's market value.
- Change in share count
- Diluted shares against the year before. Negative: fewer shares.
- Asset turnover
- Revenue divided by total assets (average of the year).